The prognostic inconsistency of the PI3K/AKT/mTOR signaling pathway in RCC may be due to the remarkable heterogeneity of RCC specimens, the limited sample size and the divergence of clinicopathological backgrounds. This evidence concerns the gene PIK3CB and renal cell carcinoma.